SG11201807250PA - Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones - Google Patents

Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones

Info

Publication number
SG11201807250PA
SG11201807250PA SG11201807250PA SG11201807250PA SG11201807250PA SG 11201807250P A SG11201807250P A SG 11201807250PA SG 11201807250P A SG11201807250P A SG 11201807250PA SG 11201807250P A SG11201807250P A SG 11201807250PA SG 11201807250P A SG11201807250P A SG 11201807250PA
Authority
SG
Singapore
Prior art keywords
international
corrizo
pct
san juan
combinations
Prior art date
Application number
SG11201807250PA
Inventor
Roshantha Chandraratna
Martin Sanders
Original Assignee
Io Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Therapeutics Inc filed Critical Io Therapeutics Inc
Publication of SG11201807250PA publication Critical patent/SG11201807250PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

WO 1715557 / 8 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/155578 Al 14 September 2017 (14.09.2017) WIPO I PCT 111111111111110111011111111111010111110 011111111111111111111111110111111111110111111 (51) International Patent Classification: A61K 45/06 (2006.01) CO7C 57/30 (2006.01) A61P 25/28 (2006.01) CO7C 57/50 (2006.01) C07C 57/03 (2006.01) (21) International Application Number: PCT/US2016/059775 (22) International Filing Date: 31 October 2016 (31.10.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/306,472 10 March 2016 (10.03.2016) US (71) Applicant: I0 THERAPEUTICS, INC. [US/US]; 26242 Via Corrizo, San Juan Capistrano, CA 92675 (US). (72) Inventors: CHANDRARATNA, Roshantha, A.; 26242 Via Corrizo, San Juan Capistrano, CA 92675 (US). SANDERS, Martin, E.; 26242 Via Corrizo, San Juan Capistrano, CA 92675 (US). (74) Agents: CULLMAN, Louis, C. et al.; K&L Gates LLP, 1 Park Plaza, 12th Floor, Irvine, CA 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: TREATMENT OF MUSCULAR DISORDERS WITH COMBINATIONS OF RXR AGONISTS AND THYROID HOR- MONES FIG. 1 Concentration (nM) (57) : The present specification provides methods of treating a muscular disorder with a combination of a RXR agonist and a thyroid hormone.
SG11201807250PA 2016-03-10 2016-10-31 Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones SG11201807250PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662306472P 2016-03-10 2016-03-10
PCT/US2016/059775 WO2017155578A1 (en) 2016-03-10 2016-10-31 Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones

Publications (1)

Publication Number Publication Date
SG11201807250PA true SG11201807250PA (en) 2018-09-27

Family

ID=59790702

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807250PA SG11201807250PA (en) 2016-03-10 2016-10-31 Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones

Country Status (16)

Country Link
US (2) US10835507B2 (en)
EP (1) EP3426303B1 (en)
JP (1) JP7169647B2 (en)
KR (1) KR20180121983A (en)
CN (1) CN109069645A (en)
AU (1) AU2016396659B2 (en)
CA (1) CA3016878C (en)
DK (1) DK3426303T3 (en)
ES (1) ES2926961T3 (en)
IL (1) IL261668B (en)
MX (1) MX2018010863A (en)
NZ (1) NZ745704A (en)
PL (1) PL3426303T3 (en)
SG (1) SG11201807250PA (en)
WO (1) WO2017155578A1 (en)
ZA (1) ZA201805940B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1937244T1 (en) 2005-09-30 2018-12-31 Io Therapeutics, Llc Treatment of cancer with specific rxr agonists
CA2858882C (en) 2011-12-13 2021-02-02 Trustees Of Dartmouth College Autoimmune disorder treatment using rxr agonists
NZ741393A (en) 2015-10-31 2018-11-30 Io Therapeutics Inc Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
PL3426303T3 (en) * 2016-03-10 2022-10-03 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
US10946001B2 (en) 2016-03-10 2021-03-16 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
AU2018335393A1 (en) * 2017-09-20 2020-04-02 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10590059B2 (en) 2017-11-17 2020-03-17 Io Therapeutics, Inc. Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2021112115A1 (en) * 2019-12-03 2021-06-10 学校法人自治医科大学 Method for maturing cardiomyocyte, method for evaluating maturation degree of cardiomyocyte, method for purifying mature cardiomyocyte, method for assisting drug development, method for treating heart disease, mature cardiomyocyte marker, reporter cell, mature cardiomyocyte, device for evaluating maturation degree of cardiomyocyte, program for evaluating maturation degree of cardiomyocyte, kit for maturing cardiomyocyte, and kit for purifying cardiomyocyte
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers
WO2023108015A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
JPH08506323A (en) 1992-11-25 1996-07-09 ラ ホヤ キャンサー リサーチ ファウンデーション RXR homodimer formation and bridged bicyclic aromatic compounds and their use in regulated gene expression
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
WO1994014777A1 (en) 1992-12-28 1994-07-07 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5917082A (en) 1995-06-06 1999-06-29 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5675033A (en) 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
JP3964478B2 (en) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heterocycle-containing carboxylic acid derivative and pharmaceutical containing the same
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6008204A (en) 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6942980B1 (en) 1995-09-01 2005-09-13 Allergan, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US6218128B1 (en) 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US20030219832A1 (en) 1996-03-11 2003-11-27 Klein Elliott S. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5763635A (en) 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US6555690B2 (en) 1996-06-21 2003-04-29 Allergan, Inc. Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
ATE253903T1 (en) 1996-12-11 2003-11-15 Dana Farber Cancer Inst Inc METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING THE GROWTH OF TUMOR CELLS CONTAINING A PPAR-GAMMA AGONIST AND A MAP KINASE INHIBITOR
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
EP1077919A1 (en) 1998-05-11 2001-02-28 Novo Nordisk A/S New compounds, their preparation and use
JP2003520758A (en) 1998-06-12 2003-07-08 リガンド・ファーマシューティカルズ・インコーポレイテッド Treatment of anti-estrogen resistant breast cancer with RXR modulator
US6403638B1 (en) 1998-10-01 2002-06-11 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6048873A (en) 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6147224A (en) 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
US6776984B1 (en) 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
US6043381A (en) 1999-05-07 2000-03-28 Allergan Sales, Inc. Process for preparing substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline derivatives
WO2001007028A2 (en) 1999-07-23 2001-02-01 Allergan Sales, Inc. The use of retinoid receptor antagonists in the treatment of prostate carcinoma
US6187750B1 (en) 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
CO5200852A1 (en) 1999-09-14 2002-09-27 Lilly Co Eli RXR MODULATORS WITH IMPROVED CEPTORS X PHARMACOLOGICAL PROFILE OF RETINOIDS
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
TWI281911B (en) 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
US20030077664A1 (en) 2001-04-18 2003-04-24 Yi Zhao Methods of screening for compounds that modulate hormone receptor activity
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
BR0209147A (en) 2001-05-08 2004-06-08 Merck Patent Gmbh Combination therapy using anti-egfr antibodies and antihormonal agents
US7173134B2 (en) 2001-09-25 2007-02-06 Smithkline Beecham Corporation Selective RXR ligands
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1485464A4 (en) 2002-03-18 2006-11-29 Gamida Cell Ltd Methods of inducing differentiation in ex vivo expanded stem cells
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
BR0309896A (en) 2002-06-04 2005-03-22 Galderma Res & Dev Compounds, use in a compound, pharmaceutical composition, cosmetic composition, cosmetic use of a composition
JP4275365B2 (en) 2002-08-06 2009-06-10 三菱電機株式会社 Combined gas insulated switchgear
US7105566B2 (en) 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
ATE356803T1 (en) 2002-11-18 2007-04-15 Galderma Res & Dev LIGANDS THAT ARE ANTAGONISTS OF RAR RECEPTORS, METHOD FOR THEIR PRODUCTION AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS
US7019034B2 (en) 2003-01-28 2006-03-28 Allergan, Inc. Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6936636B2 (en) 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
CA2535260A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Method for treating cachexia with retinoid ligands
WO2005027895A2 (en) * 2003-09-15 2005-03-31 Ordway Research Institute Thyroid hormone analogs and methods of use in angiogenesis
WO2005046726A2 (en) 2003-11-12 2005-05-26 Allergan, Inc. Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist
JP2007518804A (en) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド Composition for topical ophthalmic treatment preferably containing triamcinolone acetonide and hyaluronic acid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8105611B2 (en) 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
CA2617623A1 (en) * 2005-08-18 2007-02-22 Victoria M. Richon Combination methods of saha and targretin for treating cancer
CA2624354A1 (en) 2005-09-30 2007-04-12 Janssen Pharmaceutica N.V. Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
SI1937244T1 (en) 2005-09-30 2018-12-31 Io Therapeutics, Llc Treatment of cancer with specific rxr agonists
CN101316822A (en) 2005-09-30 2008-12-03 詹森药业有限公司 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
US20070185055A1 (en) 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
WO2008109445A1 (en) 2007-03-02 2008-09-12 Preventive Nutrient Company, Inc. Compositions and methods for treating alzheimer's disease and dementia
WO2008157394A2 (en) 2007-06-13 2008-12-24 La Jolla Institute For Allergy And Immunology Regulatory t cells and methods of making and using same
US8420077B2 (en) 2009-04-20 2013-04-16 Allergan, Inc. Silk fibroin hydrogels and uses thereof
EP2429992A4 (en) 2009-05-15 2012-11-28 Univ Kentucky Res Found Treatment of mci and alzheimer's disease
US20100298434A1 (en) 2009-05-21 2010-11-25 Claude Rouillard Neuroprotection and prevention of dopaminergic cell death by targeting nur77 translocation
JP2010280585A (en) 2009-06-02 2010-12-16 Okayama Univ Analgesic comprising rxr agonist as active ingredient
JP5902619B2 (en) 2009-07-10 2016-04-13 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ RXR agonist compounds and methods
US20120238623A1 (en) 2011-03-14 2012-09-20 Chandraratna Roshantha A Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists
EP2556827A1 (en) 2011-08-11 2013-02-13 Acadia Pharmaceuticals Inc. Treatment of neurodegenerative diseases
WO2013056232A2 (en) 2011-10-13 2013-04-18 Case Western Reserve University Rxr agonists compounds and methods
CA2858882C (en) 2011-12-13 2021-02-02 Trustees Of Dartmouth College Autoimmune disorder treatment using rxr agonists
US10653650B2 (en) * 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
WO2015059632A1 (en) 2013-10-23 2015-04-30 Acadia Pharmaceuticals Inc. Treatment of a neurodegenerative disease or disorder
JP2016537414A (en) * 2013-10-29 2016-12-01 ベスティオン、インク． Cardiac neural crest cells and methods of use thereof
WO2016144976A1 (en) 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
NZ741393A (en) * 2015-10-31 2018-11-30 Io Therapeutics Inc Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
WO2017075610A1 (en) 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists
WO2017075612A1 (en) 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of cancer with combinations of rxr agonists and thyroid hormones
US10946001B2 (en) 2016-03-10 2021-03-16 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
PL3426303T3 (en) 2016-03-10 2022-10-03 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
SG11202001479RA (en) 2017-08-31 2020-03-30 Io Therapeutics Inc Rar selective agonists in combination with immune modulators for cancer immunotherapy
AU2018335393A1 (en) 2017-09-20 2020-04-02 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists

Also Published As

Publication number Publication date
EP3426303A1 (en) 2019-01-16
NZ745704A (en) 2019-04-26
PL3426303T3 (en) 2022-10-03
DK3426303T3 (en) 2022-09-19
CA3016878A1 (en) 2017-09-14
AU2016396659B2 (en) 2019-02-14
AU2016396659A1 (en) 2018-09-13
EP3426303B1 (en) 2022-06-15
US10835507B2 (en) 2020-11-17
EP3426303A4 (en) 2019-10-30
US20210077445A1 (en) 2021-03-18
WO2017155578A1 (en) 2017-09-14
JP7169647B2 (en) 2022-11-11
IL261668A (en) 2018-10-31
KR20180121983A (en) 2018-11-09
IL261668B (en) 2022-05-01
MX2018010863A (en) 2019-01-10
JP2019511492A (en) 2019-04-25
US20190298678A1 (en) 2019-10-03
ES2926961T3 (en) 2022-10-31
ZA201805940B (en) 2019-07-31
CA3016878C (en) 2024-02-27
CN109069645A (en) 2018-12-21

Similar Documents

Publication Publication Date Title
SG11201807250PA (en) Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201810951RA (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201909949XA (en) Targeted immunotolerance
SG11201807785VA (en) Neuroactive steroids, compositions, and uses thereof
SG11201903331QA (en) Restimulation of cryopreserved tumor infiltrating lymphocytes
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11202000263QA (en) Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201907023UA (en) Method of reducing neutropenia
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201408228QA (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201908296VA (en) Biomarkers for cancer therapeutics
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201808829VA (en) Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease